The Orthopedic Market experienced healthy growth in H219 fueled by a strong Q319 in the face of difficult comps with the usual fourth-quarter bump due to the seasonality of elective procedures. Looking ahead, several key issues have the potential to impact the US market in 2020. From the economy to taxes, SmartTRAK takes a look at some of the bigger picture issues...

Steady as she goes...Soft Tissue Fixation Market on track to achieve SmartTRAK estimates for FY 2019

For the third quarter of 2019, the WW Soft Tissue Fixation Market revenue was up +3.4% YoY. Aggregate growth for the quarter benefited from solid revenue growth in the Hip Labral Repair segment, which was up +10.1% YoY, based on SmartTRAK Financial Dashboard. 

Focusing on the US region, the Soft Tissue Fixation market was up YoY. However, on a sequential basis, growth was slightly down, attributable to the seasonal nature of Sports Medicine where many surgeries are elective with Q4 generally seeing high procedure volumes. Aggregate growth for Q319 was pulled by notable growths in the Shoulder Soft Tissue Fixation and the Hip Labral Repair segments. Although Knee Soft Tissue Fixation represents the 2nd largest segment, revenue growth was marginal, with the moderate growth seen steady at slightly above  ...

Among the many topics covered in the complete, comprehensive Q319 Soft Tissue Fixation Market Recap*, including all the news, financial data, revenues, charts and SmartTRAK's expert analysis, are:

Location: Northeast region of US (NY, NJ, MA, PA)

Full-time Position

Position:

BioMedGPS, a leading strategic advisory and healthcare analytics firm serving the life sciences industry, is seeking a Director of Enterprise Sales with extensive healthcare B2B experience for its SmartTRAK Business Intelligence platform and related products. Applicant must reside in the Northeastern region of the USA for easy access to major accounts.

SmartTRAK is the first business intelligence portal that provides real time data, analytics and curated content by a team of industry experts to help medical device executives make more informed strategic decisions. SmartTRAK is utilized by leading medical device companies within the orthopedic, wound care, regenerative medicine and neuro therapeutic areas. The Director of Sales will be responsible for selling SmartTRAK’s suite of business intelligence solutions to C- suite and other senior level executives, as well as building long term strategic programs and relationships at all levels of the enterprise.

The orthopedic robotics market continues to gain momentum and validation with increasing competition and development milestones being met by key companies in the space.

The US Total Joints Market grew +3.4% in Q319, according to SmartTRAK Financial Dashboard, a sequential improvement over Q2’s 1.8% growth. While the extra selling day in the quarter boosted revenue for most Companies, slightly improved pricing and new product introductions also contributed. Wells Fargo’s Larry Biegelsen estimated recon pricing – based on Stryker, Zimmer Biomet, JNJ/DePuy Synthes, and Smith & Nephew– improved to -1.8% YoY. This sequential improvement in growth and pricing is encouraging especially in the face of a difficult comp from Q318 ...

Among the many topics covered in the complete, comprehensive Q319 Total Joints Market Recap* are:

Are you headed to Vegas for this year’s Orthopaedic Summit (OSET)? We sat down with Kristina Meyer, SmartTRAK’s Senior Analyst for Sports Medicine, for our new series, Know Before You Go, to get the scoop on what she’s looking forward to ahead of the meeting.

OSET will take place December 11-14th at the Bellagio in Las Vegas. The meeting touts itself as the “premier gathering of Total Joint (Knee, Hip, Shoulder), Foot & Ankle, Sports Medicine, Arthroscopic, Spine and Trauma Surgeons, Physician Assistants, Nurse Practitioners, Athletic Trainers, Physical and Occupational Therapists from across the globe.” Orthopaedic Summit 

SmartTRAK’s team is excited to attend and exhibit. Stop by the SmartTRAK booth, #128, to talk with Kristina and the SmartTRAK team about the latest news, trends and intelligence impacting the orthopedic industry.

1. Kristina, you are currently gearing up to attend OSET 2019. What are you looking forward to the most about the meeting?

Julianne Burns, SmartTRAK's Senior Analyst, Spine, just returned from attending the 2019 Cervical Spine Research Society's (CSRS) 47th Annual Meeting in New York City.

Julianne discusses highlights from the meeting, including what’s on the horizon for the cervical spine market and the trend toward moving cervical spine procedures to an ASC setting in an interview with SmartTRAK Managing Editor Anne Staylor.

Click the video below to hear the interview, and scroll down to read the transcript.

New products help drive sequential improvement in growth 

The WW Market for Foot & Ankle Fixation exceeded $, up +3.9%, as reported, during Q319, up sequentially due to easy YoY comps. The US Foot & Ankle Fixation market also experienced a sequential increase, resulting in +4.3% reported growth. Major players reported improved growth while smaller players announced new product introductions throughout the quarter.

Stryker posted accelerated trauma & extremities growth in Q319,
reaching $, up +9.3% in the foot & ankle fixation segment according to SmartTRAK Financial Dashboard. The foot & ankle powerhouse reported US growth was positively impacted by double-digit growth across foot, ankle and shoulder products along with the T2 Alpha Nails. Stryker recouped lost share from Q2, gaining ~4.4% share to close Q3 at 25.6%. This gain allowed Stryker to take over the number one position from...

Among the many topics covered in the complete, comprehensive Q319 Extremities Market Recap* are:

Single-injection holding the torch in a market essentially flat, impacted by ferocious pricing pressures and declines in multi-injections

For the third quarter of 2019, the US Joint Fluid market revenue was essentially flat, +0.2% vs Q318. Aggregate growth for the quarter was pulled into slightly positive territory by a solid revenue growth of 14.3% YoY in single injection, according to the recently published SmartTRAK Financial Dashboard. However, strength in that segment was barely enough to counter revenue declines in 3- and 5-injections, while the 2-injection segment is still not large enough to make a significant contribution to the overall recovery of the US Joint Fluid market.

The single-injection segment held on to the market lead for Q319. Despite pricing pressure between competitors in this segment, revenue growth further solidifies the trend that the HA market is moving to the lowest treatment cycle.  For Q319, 3-injection products dropped down, strained by heavy competition and a persistent price war. Trailing behind is the 5-injections with...

Among the many topics covered in the comprehensive Q319 US Joint Fluid Market Recap* are:

Headed to AAHKS? Our VP of Content Development for Orthopedics, Lisa Mahan, weighs in on what's trending ahead of the meeting. 

A hot topic at #AAHKS2019 this year will be the move towards outpatient joint replacement surgery with CMS moving to reimburse hospital outpatient total hip replacement and reimbursement of total knee replacement in an ASC setting.

• Outpatient hip and knee replacement surgeries are expected to comprise 57% of all nonfracture knee and hip replacements by the year 2020. ACS Focus
• AAHKS currently does not believe CMS has taken adequate action to address issues arising from